Detected ·
CellCentric
——
CellCentric closed an oversubscribed $220M Series D financing to advance pivotal clinical trials of inobrodib, a first-in-class oral treatment for multiple myeloma.
- Website
- www.cellcentric.com
- linkedin.com/company/cellcentric
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-06 16:06:28 UTC
- Signal ID
- e9a9a547-9d7f-4dcc-8fde-e9f65d18ea6c
As the API returns it
{
"id": "e9a9a547-9d7f-4dcc-8fde-e9f65d18ea6c",
"created_at": "2026-05-06T16:06:28.517247Z",
"company_name": "CellCentric",
"company_website_url": "www.cellcentric.com",
"company_linkedin_url": "https://www.linkedin.com/company/cellcentric",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*CellCentric closed an oversubscribed $220M Series D financing to advance pivotal clinical trials of inobrodib, a first-in-class oral treatment for multiple myeloma.*"
}